A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response The treatment of chronic myeloid leukaemia (CML) with imatinib mesylate (IM, Glivec) results in complete cytogenetic response (CCyR) for most patients in the chronic phase of the disease. For the majority of patients in CCyR, persisting low-level disease is demonstrable by sensitive real-time quantitative PCR (RQ-PCR) for BCR-ABL in peripheral blood. 1 We have shown an IM-resistant, quiescent (G 0 ) population of BCR-ABL þ leukaemic stem cells in primary CD34 þ -selected populations from CML patients at diagnosis that persist following IM treatment in vivo. 2 In contrast, BCR-ABL þ CD34 þ cells that are actively cycling are killed by IM in-vitro. Furthermore, IM seems to exert an antiproliferative effect on the G 0 population leading to accumulation of drug-resistant, quiescent malignant progenitor cells. 2 It is possible that this population is responsible for persistently positive BCR-ABL RQ-PCR and also for the rapid relapse observed in patients in CCyR who cease to undergo IM therapy. 3 To eradicate this population, we hypothesized that a valid strategy might involve a pulsed IM (pIM) schedule plus recombinant granulocytecolony stimulating factor (G-CSF) to push the clonal G 0 population into cell cycle and restore IM sensitivity. In light of these data, we developed a pilot, randomized, three-arm phase II study to determine the safety and toxicity of pIM with or without G-CSF in patients with chronic phase CML who had achieved CCyR (EudraCT 2004-000179-33).
Chronic phase CML patients X18 years of age, already established on IM and having achieved a CCyR (but not a complete molecular response), were eligible for this study. RQ-PCR was performed according to a standard protocol at the Adult Leukaemia Unit, Hammersmith Hospital. 4 At trial entry, patients received IM according to their established dose level (400 mg for all patients). After informed consent was obtained, patients were randomized to receive either Lenograstim (rHu-G-CSF, 263 mg, provided by Chugai Pharma UK and France) on days 24, 26 and 28 of each cycle in combination with pIM (pIM-G) therapy, pIM therapy alone or continuous IM (cIM) therapy alone (IM given at earlier dose level). For the group receiving pIM and pIM-G, IM was continued for days 1-21, and stopped until day 28 of each 4-week cycle. G-CSF was given every 48 h during the IM-free week as preclinical studies had shown a more dramatic effect with pulsed G-CSF compared with continuous G-CSF. 5 The 7-day break in IM therapy was considered long enough for drug and metabolite washout to allow reversal of the antiproliferative effects of IM on leukaemic stem cells, but short enough to be safe from the point-of-view of disease control. Treatment was administered in 4-week cycles up until a maximum of 12 cycles. Monthly BCR-ABL RQ-PCR was performed. The primary end points were: (1) safety of the combination of rHu-G-CSF plus IM. For the purposes of the trial, this was defined as X2 patients in either of the two experimental arms experiencing severe adverse events or Grade 3/4 toxicity (according to National Cancer Institute (NCI) toxicity criteria) attributable to the study treatment, (2) safety of IM interruption, that is, no apparent loss of molecular, CCyR or complete haematological response above that seen in the control arm (proportion of patients progressing). The secondary end point was molecular response to IM interruption þ /À G-CSF.
Between October 2004 and September 2006, 45 patients were recruited to the study as planned (15 in each arm) from five centres in the UK and one in France. The relevant patient characteristics are shown in Table 1 . Non-haematological grade I and II toxicities were in keeping with the known side effect profile of both the study drugs (data not shown). Significantly, more bone pain and arthralgias were observed in the pIM-G arm (P-values 0.018 and 0.009, respectively), almost certainly relating to lenograstim. No haematological toxicity was observed and no grade III or IV toxicities occurred as a result of study treatment. The treatment, therefore, seemed to be well tolerated.
In total, four patients exhibited disease progression within the study period (Table 2 ) manifested by loss of CCyR or development of an ABL-kinase domain mutation and both in the experimental arms (three on pIM and one on pIM-G). Three of these patients (patients 1, 3 and 4) regained major molecular response (MMR), using nilotinib or 600 mg of IM once daily after treatment off study. Patient 2 succumbed to blast phase CML. In addition, three patients lost MMR (patients 5-7) all of whom were maintained on study treatment for full 12 months. Patients 6 and 7, both on the experimental arms (pIM-G and pIM, respectively), regained MMR when re-established on daily IM therapy after study completion. Thus, 6 out of 30 patients (20%) in the two experimental arms exhibited loss of MMR or CCyR (patients 1-4, 6 and 7 in Table 3 ), as compared with only one (7%, patient 5) in the continuous IM study arm. Five patients in total (patients 1, 3, 4, 6 and 7 in Table 3 ) regained MMR when restarted on daily IM or nilotinib, suggesting that for these patients the experimental arms may have contributed to loss of disease control; however, simple fluctuations in BCR-ABL levels in what is a heterogeneous population cannot be discounted. There were no significant differences when all three arms were compared for loss of response vs stable or improved response (P ¼ 0.3), although this small study was not powered to detect small differences. A secondary end point of the study was whether there was any change in BCR-ABL levels by RQ-PCR over the 12-month study period between the study arms. Using ANCOVA (analysis of covariance) to analyse change in levels, no significant differences were seen (Supplementary Table) between the study arms, although again the study was not powered to detect small differences. In terms of the natural history of CML, the study period (12 months) was relatively short for a disease, in which median survival on IM is 
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now being estimated at X20 years. Identifying a measurable depletion of the BCR-ABL þ -quiescent leukaemic stem cell pool may simply not be feasible over this period of time, which was chosen as a result of practical issues with running such a study and ethical concerns regarding the safety of IM dose interruption. Complementary biological studies to look at the CD34 þ compartment may also be important to detect changes over time.
